CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the...

CEO Kevin Finney describes the rationale for using a TRβ agonist and how this program leverages Autobahn's brain-targeting chemistry...

He talks about the two different categories of companies based on their use of AI, and discusses what he looks for when evaluating them.

Yusuf Erkul explains the four components that go into getting mRNA to the right location in the body and to be translated in the right...

He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more.

He explains how the goal of Eigen is to help up-regulate antigens of interest and how technologies today allow a smaller startup to...

NYSE's Eric Dimise and Decoding Bio's Amee Kapadia describe the ways that AI is already impacting healthcare today and where it might be...

CEO Al Gianchetti explains that the company recently released final results from a phase 1/2 clinical trial and how XyloCor is set to...

Entrepreneurship and Business Development Director Marco Delise describes the facilities available at SBC and the types of companies that...

Co-founder and CEO Dan Mandell discusses the company’s approach, and describes how this will allow GRObio to advance its lead program for...

David Klein describes how the digital therapeutics space works and highlights Click's programs and partnerships with large pharmaceutical...

CEO Mahendra Deonarian describes the potential advantages of this approach over traditional ADCs and talks about the company's lead...

Founder & CEO Charles Large describes the scientific foundation Autifony has built in ion channel science and how the company is...

CEO Michael Parini describes how clinical results Spur has seen to date in six patients, with more data to come later this year, has...

From a partnering event being held at MassBio's HQ in Kendall Square, Ken Takeshita describes Daiichi's targets under development beyond...

Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an...

Dave Latshaw II predicts how AI might affect organizations of different sizes in biopharma and explains the various ways BioPhy is using...

He provides an in-depth discussion on this week's uniQure data, and upcoming data from Lexeo. Plus, comments on Alnylam, Dyne,...

CEO William Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients...

Noubar Afeyan describes some areas that he sees the funding being deployed, his take on the current state of biotech, the IPO market,...